Flex has collaborated with Novo Nordisk for the development of digital health solutions for diabetes patients.
After rigorous evaluation, Novo Nordisk selected the medical-grade BrightInsight platform from Flex Digital Health to build and operate these solutions and securely manage millions of its smart medical devices and the corresponding data within a regulatory-compliant environment.
BrightInsight provides a unified IoT platform that enables organizations to develop and host digital health devices, apps and algorithms at scale while maintaining compliance with privacy, security and regulatory requirements across the globe. Compared to building a custom platform from scratch, BrightInsight’s robust functionality facilitates lower costs and accelerates time to market.
Flex digital health SVP and MD Kal Patel said: “Traditional methods of managing diabetes have not kept pace with a world moving at digital.
“BrightInsight securely unlocks real-world data and actionable insights, enabling pharma and medtech companies to develop advanced, regulated digital health solutions that enable automated clinical decisions and better engagement between clinicians and people with diabetes.”
By collaborating with Flex and utilizing Flex’s established platform, BrightInsight, Novo Nordisk can focus on developing innovative medicines with the goal of improving patient outcomes.
Novo Nordisk commercial innovation corporate vice president Anders Dyhr Toft said: “Addressing the growing diabetes epidemic takes more than best-in-class medicines alone. We need to engage with people on their level and integrate with the solutions they are already using to manage their diabetes.
“Medical-grade digital health platforms like BrightInsight are key to helping us improve the dialogue between people with diabetes and their caregivers.”
BrightInsight is an advanced, medical-grade managed service platform that can capture and analyze data from connected medical devices, combination products, apps or Software as a Medical Device (SaMD) in a secure, regulatory-compliant environment. BrightInsight’s Device Master File has been accepted by the FDA and Flex Digital Health is ISO 13485:2016 certified.
This announcement further builds on Flex’s current Sketch-to-Scale engagement to help design and manufacture elements of Novo Nordisk’s new connected insulin pens.
The new partnership with Novo Nordisk follows another recent milestone for Flex Digital Health, the inauguration of the BrightInsight Clinical Board, which was established to incorporate physician insight and workflow experience in the development of digital health tools.
Flex is the Sketch-to-Scale solutions provider that designs and builds Intelligent Products for a Connected World.
With approximately 200,000 professionals across 30 countries, Flex provides innovative design, engineering, manufacturing, real-time supply chain insight and logistics services to companies of all sizes in various industries and end-markets.
Source: Company Press Release